OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Itch as a critical factor in impaired health-related quality of life in patients with plaque psoriasis achieving clear or almost-clear skin: Analysis of the single-arm, open-label, multicenter, prospective ProLOGUE study
Takuya Miyagi, Yasumasa Kanai, Kenta Murotani, et al.
JAAD International (2022) Vol. 8, pp. 146-153
Open Access | Times Cited: 7
Takuya Miyagi, Yasumasa Kanai, Kenta Murotani, et al.
JAAD International (2022) Vol. 8, pp. 146-153
Open Access | Times Cited: 7
Showing 7 citing articles:
Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis
Matthias Augustin, Alice B. Gottlieb, Mark Lebwohl, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 10, pp. 2841-2857
Open Access | Times Cited: 5
Matthias Augustin, Alice B. Gottlieb, Mark Lebwohl, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 10, pp. 2841-2857
Open Access | Times Cited: 5
A Canadian Real-World Study of Fixed-DOSE combination of Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion for the Treatment of Moderate-to-Severe Plaque Psoriasis
Ronald Vender, Charles Lynde, Vimal H. Prajapati, et al.
Clinical Therapeutics (2025)
Closed Access
Ronald Vender, Charles Lynde, Vimal H. Prajapati, et al.
Clinical Therapeutics (2025)
Closed Access
Quality of life and patient-reported symptoms in a Phase 4, real-world study of tildrakizumab in patients with moderate-to-severe psoriasis: Week 28 interim analysis
Neal Bhatia, Jayme Heim, Brad Schenkel, et al.
Journal of Dermatological Treatment (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 6
Neal Bhatia, Jayme Heim, Brad Schenkel, et al.
Journal of Dermatological Treatment (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 6
Patients with Persistent Mild Psoriasis after Treatment with Ustekinumab Achieved Greater Improvements in Skin Clearance and Patient-reported Outcomes after Switching to Guselkumab in the Phase 3 NAVIGATE Trial
Enzo Errichetti, Peter Wolf, Saakshi Khattri, et al.
Acta Dermato Venereologica (2024) Vol. 104, pp. adv41053-adv41053
Open Access | Times Cited: 1
Enzo Errichetti, Peter Wolf, Saakshi Khattri, et al.
Acta Dermato Venereologica (2024) Vol. 104, pp. adv41053-adv41053
Open Access | Times Cited: 1
Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial
L. Puig, Antonio Costanzo, E.M.G.J. de Jong, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 9, pp. 2539-2558
Open Access
L. Puig, Antonio Costanzo, E.M.G.J. de Jong, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 9, pp. 2539-2558
Open Access
This Month in JAAD International: July 2023: Quality of life and itch
Jonathan Kantor
Journal of the American Academy of Dermatology (2023) Vol. 89, Iss. 1, pp. 33-33
Closed Access
Jonathan Kantor
Journal of the American Academy of Dermatology (2023) Vol. 89, Iss. 1, pp. 33-33
Closed Access
This Month in JAAD International: December 2023: Patient-reported outcome measures
Jonathan Kantor
Journal of the American Academy of Dermatology (2023) Vol. 89, Iss. 6, pp. 1126-1126
Closed Access
Jonathan Kantor
Journal of the American Academy of Dermatology (2023) Vol. 89, Iss. 6, pp. 1126-1126
Closed Access
